English
简体中文
Total: £ 56.28
Published Date: 2025-10-31 | Pages: 124 | Tables: 118 | Pharma & Healthcare
The global Non-beta-lactam Antibiotics market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Non-beta-lactam antibiotics are a broad class of antimicrobial agents that do not contain the beta-lactam ring structure found in penicillins, cephalosporins, and other similar antibiotics. These drugs are crucial in treating bacterial infections, particularly those caused by bacteria resistant to beta-lactam antibiotics. Non-beta-lactam antibiotics encompass various types, including macrolides, fluoroquinolones, tetracyclines, and aminoglycosides, each working through different mechanisms to inhibit bacterial growth or kill bacteria. Their diverse modes of action and range of target bacteria make them essential tools in combating a wide array of infectious diseases.
From a downstream perspective, Hospital accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Non-beta-lactam Antibiotics leading manufacturers including Teva, Novartis, Cipla, Pfizer, Fresenius Kabi, Sun Pharmaceutical, Hikma Pharmaceuticals, Lannett Company, FangYuan Pharmaceutical, etc., dominate supply; the top five capture approximately % of global revenue, with Teva leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Non-beta-lactam Antibiotics market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Teva
Novartis
Cipla
Pfizer
Fresenius Kabi
Sun Pharmaceutical
Hikma Pharmaceuticals
Lannett Company
FangYuan Pharmaceutical
Segment by Type
Aminoglycosides
Tetracyclines
Macrolides
Chloramphenicol
Lincomycin
Others
Segment by Application
Hospital
Clinic
Other
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Non-beta-lactam Antibiotics study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 Introduction to Non-beta-lactam Antibiotics: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Non-beta-lactam Antibiotics Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Aminoglycosides
1.2.3 Tetracyclines
1.2.4 Macrolides
1.2.5 Chloramphenicol
1.2.6 Lincomycin
1.2.7 Others
1.3 Market Segmentation by Application
1.3.1 Global Non-beta-lactam Antibiotics Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Non-beta-lactam Antibiotics Revenue Estimates and Forecasts 2020-2031
2.2 Global Non-beta-lactam Antibiotics Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Non-beta-lactam Antibiotics Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Non-beta-lactam Antibiotics Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Aminoglycosides Market Size by Players
3.3.2 Tetracyclines Market Size by Players
3.3.3 Macrolides Market Size by Players
3.3.4 Chloramphenicol Market Size by Players
3.3.5 Lincomycin Market Size by Players
3.3.6 Others Market Size by Players
3.4 Global Non-beta-lactam Antibiotics Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Non-beta-lactam Antibiotics Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Non-beta-lactam Antibiotics Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Non-beta-lactam Antibiotics Market Size by Type (2020-2031)
6.4 North America Non-beta-lactam Antibiotics Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Non-beta-lactam Antibiotics Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Non-beta-lactam Antibiotics Market Size by Type (2020-2031)
7.4 Europe Non-beta-lactam Antibiotics Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Non-beta-lactam Antibiotics Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Non-beta-lactam Antibiotics Market Size by Type (2020-2031)
8.4 Asia-Pacific Non-beta-lactam Antibiotics Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Non-beta-lactam Antibiotics Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Non-beta-lactam Antibiotics Market Size by Type (2020-2031)
9.4 Central and South America Non-beta-lactam Antibiotics Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Non-beta-lactam Antibiotics Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Non-beta-lactam Antibiotics Market Size by Type (2020-2031)
10.4 Middle East and Africa Non-beta-lactam Antibiotics Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Non-beta-lactam Antibiotics Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Teva
11.1.1 Teva Corporation Information
11.1.2 Teva Business Overview
11.1.3 Teva Non-beta-lactam Antibiotics Product Features and Attributes
11.1.4 Teva Non-beta-lactam Antibiotics Revenue and Gross Margin (2020-2025)
11.1.5 Teva Non-beta-lactam Antibiotics Revenue by Product in 2024
11.1.6 Teva Non-beta-lactam Antibiotics Revenue by Application in 2024
11.1.7 Teva Non-beta-lactam Antibiotics Revenue by Geographic Area in 2024
11.1.8 Teva Non-beta-lactam Antibiotics SWOT Analysis
11.1.9 Teva Recent Developments
11.2 Novartis
11.2.1 Novartis Corporation Information
11.2.2 Novartis Business Overview
11.2.3 Novartis Non-beta-lactam Antibiotics Product Features and Attributes
11.2.4 Novartis Non-beta-lactam Antibiotics Revenue and Gross Margin (2020-2025)
11.2.5 Novartis Non-beta-lactam Antibiotics Revenue by Product in 2024
11.2.6 Novartis Non-beta-lactam Antibiotics Revenue by Application in 2024
11.2.7 Novartis Non-beta-lactam Antibiotics Revenue by Geographic Area in 2024
11.2.8 Novartis Non-beta-lactam Antibiotics SWOT Analysis
11.2.9 Novartis Recent Developments
11.3 Cipla
11.3.1 Cipla Corporation Information
11.3.2 Cipla Business Overview
11.3.3 Cipla Non-beta-lactam Antibiotics Product Features and Attributes
11.3.4 Cipla Non-beta-lactam Antibiotics Revenue and Gross Margin (2020-2025)
11.3.5 Cipla Non-beta-lactam Antibiotics Revenue by Product in 2024
11.3.6 Cipla Non-beta-lactam Antibiotics Revenue by Application in 2024
11.3.7 Cipla Non-beta-lactam Antibiotics Revenue by Geographic Area in 2024
11.3.8 Cipla Non-beta-lactam Antibiotics SWOT Analysis
11.3.9 Cipla Recent Developments
11.4 Pfizer
11.4.1 Pfizer Corporation Information
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Non-beta-lactam Antibiotics Product Features and Attributes
11.4.4 Pfizer Non-beta-lactam Antibiotics Revenue and Gross Margin (2020-2025)
11.4.5 Pfizer Non-beta-lactam Antibiotics Revenue by Product in 2024
11.4.6 Pfizer Non-beta-lactam Antibiotics Revenue by Application in 2024
11.4.7 Pfizer Non-beta-lactam Antibiotics Revenue by Geographic Area in 2024
11.4.8 Pfizer Non-beta-lactam Antibiotics SWOT Analysis
11.4.9 Pfizer Recent Developments
11.5 Fresenius Kabi
11.5.1 Fresenius Kabi Corporation Information
11.5.2 Fresenius Kabi Business Overview
11.5.3 Fresenius Kabi Non-beta-lactam Antibiotics Product Features and Attributes
11.5.4 Fresenius Kabi Non-beta-lactam Antibiotics Revenue and Gross Margin (2020-2025)
11.5.5 Fresenius Kabi Non-beta-lactam Antibiotics Revenue by Product in 2024
11.5.6 Fresenius Kabi Non-beta-lactam Antibiotics Revenue by Application in 2024
11.5.7 Fresenius Kabi Non-beta-lactam Antibiotics Revenue by Geographic Area in 2024
11.5.8 Fresenius Kabi Non-beta-lactam Antibiotics SWOT Analysis
11.5.9 Fresenius Kabi Recent Developments
11.6 Sun Pharmaceutical
11.6.1 Sun Pharmaceutical Corporation Information
11.6.2 Sun Pharmaceutical Business Overview
11.6.3 Sun Pharmaceutical Non-beta-lactam Antibiotics Product Features and Attributes
11.6.4 Sun Pharmaceutical Non-beta-lactam Antibiotics Revenue and Gross Margin (2020-2025)
11.6.5 Sun Pharmaceutical Recent Developments
11.7 Hikma Pharmaceuticals
11.7.1 Hikma Pharmaceuticals Corporation Information
11.7.2 Hikma Pharmaceuticals Business Overview
11.7.3 Hikma Pharmaceuticals Non-beta-lactam Antibiotics Product Features and Attributes
11.7.4 Hikma Pharmaceuticals Non-beta-lactam Antibiotics Revenue and Gross Margin (2020-2025)
11.7.5 Hikma Pharmaceuticals Recent Developments
11.8 Lannett Company
11.8.1 Lannett Company Corporation Information
11.8.2 Lannett Company Business Overview
11.8.3 Lannett Company Non-beta-lactam Antibiotics Product Features and Attributes
11.8.4 Lannett Company Non-beta-lactam Antibiotics Revenue and Gross Margin (2020-2025)
11.8.5 Lannett Company Recent Developments
11.9 FangYuan Pharmaceutical
11.9.1 FangYuan Pharmaceutical Corporation Information
11.9.2 FangYuan Pharmaceutical Business Overview
11.9.3 FangYuan Pharmaceutical Non-beta-lactam Antibiotics Product Features and Attributes
11.9.4 FangYuan Pharmaceutical Non-beta-lactam Antibiotics Revenue and Gross Margin (2020-2025)
11.9.5 FangYuan Pharmaceutical Recent Developments
12 Non-beta-lactam AntibioticsIndustry Chain Analysis
12.1 Non-beta-lactam Antibiotics Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Non-beta-lactam Antibiotics Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Non-beta-lactam Antibiotics Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Non-beta-lactam Antibiotics Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Non-beta-lactam Antibiotics Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Non-beta-lactam Antibiotics Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Non-beta-lactam Antibiotics Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Non-beta-lactam Antibiotics Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Non-beta-lactam Antibiotics Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Non-beta-lactam Antibiotics Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Non-beta-lactam Antibiotics by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-beta-lactam Antibiotics as of 2024)
Table 11. Global Non-beta-lactam Antibiotics Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Non-beta-lactam Antibiotics Companies Headquarters
Table 13. Global Non-beta-lactam Antibiotics Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Non-beta-lactam Antibiotics Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Non-beta-lactam Antibiotics Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Non-beta-lactam Antibiotics Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Non-beta-lactam Antibiotics Revenue by Application (2026-2031) & (US$ Million)
Table 21. Non-beta-lactam Antibiotics High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Non-beta-lactam Antibiotics Growth Accelerators and Market Barriers
Table 25. North America Non-beta-lactam Antibiotics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Non-beta-lactam Antibiotics Growth Accelerators and Market Barriers
Table 27. Europe Non-beta-lactam Antibiotics Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Non-beta-lactam Antibiotics Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Non-beta-lactam Antibiotics Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Non-beta-lactam Antibiotics Investment Opportunities and Key Challenges
Table 31. Central and South America Non-beta-lactam Antibiotics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Non-beta-lactam Antibiotics Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Non-beta-lactam Antibiotics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Teva Corporation Information
Table 35. Teva Description and Major Businesses
Table 36. Teva Product Features and Attributes
Table 37. Teva Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Teva Revenue Proportion by Product in 2024
Table 39. Teva Revenue Proportion by Application in 2024
Table 40. Teva Revenue Proportion by Geographic Area in 2024
Table 41. Teva Non-beta-lactam Antibiotics SWOT Analysis
Table 42. Teva Recent Developments
Table 43. Novartis Corporation Information
Table 44. Novartis Description and Major Businesses
Table 45. Novartis Product Features and Attributes
Table 46. Novartis Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Novartis Revenue Proportion by Product in 2024
Table 48. Novartis Revenue Proportion by Application in 2024
Table 49. Novartis Revenue Proportion by Geographic Area in 2024
Table 50. Novartis Non-beta-lactam Antibiotics SWOT Analysis
Table 51. Novartis Recent Developments
Table 52. Cipla Corporation Information
Table 53. Cipla Description and Major Businesses
Table 54. Cipla Product Features and Attributes
Table 55. Cipla Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Cipla Revenue Proportion by Product in 2024
Table 57. Cipla Revenue Proportion by Application in 2024
Table 58. Cipla Revenue Proportion by Geographic Area in 2024
Table 59. Cipla Non-beta-lactam Antibiotics SWOT Analysis
Table 60. Cipla Recent Developments
Table 61. Pfizer Corporation Information
Table 62. Pfizer Description and Major Businesses
Table 63. Pfizer Product Features and Attributes
Table 64. Pfizer Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Pfizer Revenue Proportion by Product in 2024
Table 66. Pfizer Revenue Proportion by Application in 2024
Table 67. Pfizer Revenue Proportion by Geographic Area in 2024
Table 68. Pfizer Non-beta-lactam Antibiotics SWOT Analysis
Table 69. Pfizer Recent Developments
Table 70. Fresenius Kabi Corporation Information
Table 71. Fresenius Kabi Description and Major Businesses
Table 72. Fresenius Kabi Product Features and Attributes
Table 73. Fresenius Kabi Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Fresenius Kabi Revenue Proportion by Product in 2024
Table 75. Fresenius Kabi Revenue Proportion by Application in 2024
Table 76. Fresenius Kabi Revenue Proportion by Geographic Area in 2024
Table 77. Fresenius Kabi Non-beta-lactam Antibiotics SWOT Analysis
Table 78. Fresenius Kabi Recent Developments
Table 79. Sun Pharmaceutical Corporation Information
Table 80. Sun Pharmaceutical Description and Major Businesses
Table 81. Sun Pharmaceutical Product Features and Attributes
Table 82. Sun Pharmaceutical Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Sun Pharmaceutical Recent Developments
Table 84. Hikma Pharmaceuticals Corporation Information
Table 85. Hikma Pharmaceuticals Description and Major Businesses
Table 86. Hikma Pharmaceuticals Product Features and Attributes
Table 87. Hikma Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Hikma Pharmaceuticals Recent Developments
Table 89. Lannett Company Corporation Information
Table 90. Lannett Company Description and Major Businesses
Table 91. Lannett Company Product Features and Attributes
Table 92. Lannett Company Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Lannett Company Recent Developments
Table 94. FangYuan Pharmaceutical Corporation Information
Table 95. FangYuan Pharmaceutical Description and Major Businesses
Table 96. FangYuan Pharmaceutical Product Features and Attributes
Table 97. FangYuan Pharmaceutical Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. FangYuan Pharmaceutical Recent Developments
Table 99. Raw Materials Key Suppliers
Table 100. Distributors List
Table 101. Market Trends and Market Evolution
Table 102. Market Drivers and Opportunities
Table 103. Market Challenges, Risks, and Restraints
Table 104. Research Programs/Design for This Report
Table 105. Key Data Information from Secondary Sources
Table 106. Key Data Information from Primary Sources
List of Figures
Figure 1. Non-beta-lactam Antibiotics Product Picture
Figure 2. Global Non-beta-lactam Antibiotics Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Aminoglycosides Product Picture
Figure 4. Tetracyclines Product Picture
Figure 5. Macrolides Product Picture
Figure 6. Chloramphenicol Product Picture
Figure 7. Lincomycin Product Picture
Figure 8. Others Product Picture
Figure 9. Global Non-beta-lactam Antibiotics Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Other
Figure 13. Non-beta-lactam Antibiotics Report Years Considered
Figure 14. Global Non-beta-lactam Antibiotics Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Non-beta-lactam Antibiotics Revenue (2020-2031) & (US$ Million)
Figure 16. Global Non-beta-lactam Antibiotics Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 17. Global Non-beta-lactam Antibiotics Revenue Market Share by Region (2020-2031)
Figure 18. Global Non-beta-lactam Antibiotics Revenue Market Share Ranking (2024)
Figure 19. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 20. Aminoglycosides Revenue Market Share by Player in 2024
Figure 21. Tetracyclines Revenue Market Share by Player in 2024
Figure 22. Macrolides Revenue Market Share by Player in 2024
Figure 23. Chloramphenicol Revenue Market Share by Player in 2024
Figure 24. Lincomycin Revenue Market Share by Player in 2024
Figure 25. Others Revenue Market Share by Player in 2024
Figure 26. Global Non-beta-lactam Antibiotics Revenue Market Share by Type (2020-2031)
Figure 27. Global Non-beta-lactam Antibiotics Revenue Market Share by Application (2020-2031)
Figure 28. North America Non-beta-lactam Antibiotics Revenue YoY (2020-2031) & (US$ Million)
Figure 29. North America Top 5 Players Non-beta-lactam Antibiotics Revenue (US$ Million) in 2024
Figure 30. North America Non-beta-lactam Antibiotics Revenue (US$ Million) by Type (2020 - 2031)
Figure 31. North America Non-beta-lactam Antibiotics Revenue (US$ Million) by Application (2020-2031)
Figure 32. US Non-beta-lactam Antibiotics Revenue (2020-2031) & (US$ Million)
Figure 33. Canada Non-beta-lactam Antibiotics Revenue (2020-2031) & (US$ Million)
Figure 34. Mexico Non-beta-lactam Antibiotics Revenue (2020-2031) & (US$ Million)
Figure 35. Europe Non-beta-lactam Antibiotics Revenue YoY (2020-2031) & (US$ Million)
Figure 36. Europe Top 5 Players Non-beta-lactam Antibiotics Revenue (US$ Million) in 2024
Figure 37. Europe Non-beta-lactam Antibiotics Revenue (US$ Million) by Type (2020-2031)
Figure 38. Europe Non-beta-lactam Antibiotics Revenue (US$ Million) by Application (2020-2031)
Figure 39. Germany Non-beta-lactam Antibiotics Revenue (2020-2031) & (US$ Million)
Figure 40. France Non-beta-lactam Antibiotics Revenue (2020-2031) & (US$ Million)
Figure 41. U.K. Non-beta-lactam Antibiotics Revenue (2020-2031) & (US$ Million)
Figure 42. Italy Non-beta-lactam Antibiotics Revenue (2020-2031) & (US$ Million)
Figure 43. Russia Non-beta-lactam Antibiotics Revenue (2020-2031) & (US$ Million)
Figure 44. Asia-Pacific Non-beta-lactam Antibiotics Revenue YoY (2020-2031) & (US$ Million)
Figure 45. Asia-Pacific Top 8 Players Non-beta-lactam Antibiotics Revenue (US$ Million) in 2024
Figure 46. Asia-Pacific Non-beta-lactam Antibiotics Revenue (US$ Million) by Type (2020-2031)
Figure 47. Asia-Pacific Non-beta-lactam Antibiotics Revenue (US$ Million) by Application (2020-2031)
Figure 48. Indonesia Non-beta-lactam Antibiotics Revenue (2020-2031) & (US$ Million)
Figure 49. Japan Non-beta-lactam Antibiotics Revenue (2020-2031) & (US$ Million)
Figure 50. South Korea Non-beta-lactam Antibiotics Revenue (2020-2031) & (US$ Million)
Figure 51. Australia Non-beta-lactam Antibiotics Revenue (2020-2031) & (US$ Million)
Figure 52. India Non-beta-lactam Antibiotics Revenue (2020-2031) & (US$ Million)
Figure 53. Indonesia Non-beta-lactam Antibiotics Revenue (2020-2031) & (US$ Million)
Figure 54. Vietnam Non-beta-lactam Antibiotics Revenue (2020-2031) & (US$ Million)
Figure 55. Malaysia Non-beta-lactam Antibiotics Revenue (2020-2031) & (US$ Million)
Figure 56. Philippines Non-beta-lactam Antibiotics Revenue (2020-2031) & (US$ Million)
Figure 57. Singapore Non-beta-lactam Antibiotics Revenue (2020-2031) & (US$ Million)
Figure 58. Central and South America Non-beta-lactam Antibiotics Revenue YoY (2020-2031) & (US$ Million)
Figure 59. Central and South America Top 5 Players Non-beta-lactam Antibiotics Revenue (US$ Million) in 2024
Figure 60. Central and South America Non-beta-lactam Antibiotics Revenue (US$ Million) by Type (2020-2031)
Figure 61. Central and South America Non-beta-lactam Antibiotics Revenue (US$ Million) by Application (2020-2031)
Figure 62. Brazil Non-beta-lactam Antibiotics Revenue (2020-2025) & (US$ Million)
Figure 63. Argentina Non-beta-lactam Antibiotics Revenue (2020-2025) & (US$ Million)
Figure 64. Middle East and Africa Non-beta-lactam Antibiotics Revenue YoY (2020-2031) & (US$ Million)
Figure 65. Middle East and Africa Top 5 Players Non-beta-lactam Antibiotics Revenue (US$ Million) in 2024
Figure 66. South America Non-beta-lactam Antibiotics Revenue (US$ Million) by Type (2020-2031)
Figure 67. Middle East and Africa Non-beta-lactam Antibiotics Revenue (US$ Million) by Application (2020-2031)
Figure 68. GCC Countries Non-beta-lactam Antibiotics Revenue (2020-2025) & (US$ Million)
Figure 69. Israel Non-beta-lactam Antibiotics Revenue (2020-2025) & (US$ Million)
Figure 70. Egypt Non-beta-lactam Antibiotics Revenue (2020-2025) & (US$ Million)
Figure 71. South Africa Non-beta-lactam Antibiotics Revenue (2020-2025) & (US$ Million)
Figure 72. Non-beta-lactam Antibiotics Industry Chain Mapping
Figure 73. Channels of Distribution (Direct Vs Distribution)
Figure 74. Bottom-up and Top-down Approaches for This Report
Figure 75. Data Triangulation
Figure 76. Key Executives Interviewed
